- Home
- IPHA vs OBIO Comparison
IPHA vs OBIO Comparison
Compare IPHA & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- OBIO
- Stock Information
- Founded
- IPHA 1999
- OBIO 2017
- Country
- IPHA France
- OBIO United States
- Employees
- IPHA N/A
- OBIO N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- IPHA Health Care
- OBIO Health Care
- Exchange
- IPHA Nasdaq
- OBIO Nasdaq
- Market Cap
- IPHA 178.0M
- OBIO 200.1M
- IPO Year
- IPHA 2019
- OBIO N/A
- Fundamental
- Price
- IPHA $2.07
- OBIO $4.79
- Analyst Decision
- IPHA Strong Buy
- OBIO Strong Buy
- Analyst Count
- IPHA 1
- OBIO 4
- Target Price
- IPHA $11.50
- OBIO $15.75
- AVG Volume (30 Days)
- IPHA 1.5M
- OBIO 64.0K
- Earning Date
- IPHA 09-12-2024
- OBIO 11-12-2024
- Dividend Yield
- IPHA N/A
- OBIO N/A
- EPS Growth
- IPHA N/A
- OBIO N/A
- EPS
- IPHA N/A
- OBIO N/A
- Revenue
- IPHA $36,202,722.00
- OBIO $2,647,000.00
- Revenue This Year
- IPHA N/A
- OBIO $12.39
- Revenue Next Year
- IPHA $102.87
- OBIO $120.99
- P/E Ratio
- IPHA N/A
- OBIO N/A
- Revenue Growth
- IPHA N/A
- OBIO N/A
- 52 Week Low
- IPHA $1.29
- OBIO $4.22
- 52 Week High
- IPHA $3.51
- OBIO $10.44
- Technical
- Relative Strength Index (RSI)
- IPHA 53.12
- OBIO 37.52
- Support Level
- IPHA $1.47
- OBIO $4.36
- Resistance Level
- IPHA $2.36
- OBIO $5.28
- Average True Range (ATR)
- IPHA 0.32
- OBIO 0.45
- MACD
- IPHA 0.06
- OBIO -0.07
- Stochastic Oscillator
- IPHA 29.99
- OBIO 23.65
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.